Skip to main content

Table 2 Multivariate Cox proportional hazard analysis with overall survival as endpoint

From: Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer

 

Patients, n

Multivariate HR (95% CI)

P value

Age

 < 60

70

1.00 (ref)

 

 60–74

176

1.70 (0.91–3.18)

0.099

 ≥ 75

173

3.42 (1.84–6.34)

< 0.001

Stage

 I

78

1.00 (ref)

 

 II

168

1.24 (0.66–2.34)

0.498

 III

117

2.32 (1.24–4.34)

0.009

 IV

56

11.10 (5.91–20.85)

< 0.001

ZNF331 methylation

ZNF331 unmeth

121

1.00 (ref)

 

ZNF331 meth

298

1.44 (0.97–2.14)

0.069

  1. Variables not selected by the backward likelihood method to be included in the final model: series, gender, CIMP-, MSI-, and BRAF mutation status
  2. Meth methylated, unmeth unmethylated